AUTL News and Press, Autolus Therapeutics plc From 05/12/21

Autolus Therapeutics ([[AUTL]] +33.3%) has surged today in reaction to impressive results from a Phase 1 trial for its CD19 CAR T cell therapy AUTO1 in relapsed / refractory (r/r) indolent B cell lymphomas ((IBCL)).The data is included in an abstract presentation to be unveiled at t...

Gainers: Curis (CRIS) +53%.Second Sight Medical Products (EYES) +44%.Summit Wireless Technologies (WISA) +39%.Barnwell Industries (BRN) +36%.Autolus Therapeutics (AUTL) +31%.Ra Medical Systems (RMED) +29%.ShotSpotter (SSTI) +23%.Ideal Power (IPWR) +22%.Minerva Neurosciences (NE...

AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients No high-grade cytokine release syndrome or neurotoxicity observed LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage bi...

Autolus Therapeutics Plc (AUTL) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Lucinda Crabtree - Vice President of Investor Relations Christian Itin - Chairman and Chief Executive Officer Andrew Oakley - Chief Financial Officer Conference Call Participants Mara ...

Autolus Therapeutics (AUTL): Q1 GAAP EPS of -$0.53 beats by $0.11.Revenue of $0.27M (-20.6% Y/Y) misses by $0.07M.Cash at March 31, 2021 totaled $239.0 million, as compared to $153.3 million at December 31, 2020.Shares +0.19% PM.Press Release For further detail...

LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended March 31, 2021. “...

We are circling back today on Autolus Therapeutics, for the first time since we did an in-depth piece on this name late in 2019. Development of candidates has been a bit slower than anticipated but it has some trial milestones on the horizon and just addressed near-term funding needs....

LONDON, April 26, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2021 financial results and operational highlight...

Autolus Therapeutics (AUTL) has received innovative licensing and access pathway ((ILAP)) designation from the U.K. Medicines and Healthcare products Regulatory Agency ((MHRA)) for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma ((PTCL)). ILAP was launched ...

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from th...